Sweet's syndrome associated with sargramostim (granulocyte-macrophage colony stimulating factor) treatment

American Journal of Hematology
Geetika KumarMichael A Baumann

Abstract

Sweet's syndrome is an acute febrile neutrophilic dermatosis that is a known complication of the administration of filgrastim, a drug that causes increased neutrophil proliferation and differentiation. This complication has not previously been reported during treatment with sargramostim, a hematopoietic cytokine with activity that overlaps filgrastim. We report a case of Sweet's syndrome in association with sargramostim treatment following chemotherapy for acute myelogenous leukemia. A suspected second episode occurred after subsequent chemotherapy and sargramostim treatment. Physicians should be aware of this possible association because the signs and symptoms of Sweet's syndrome are easily mistaken as being due to infection.

References

Jun 15, 1992·Annals of Internal Medicine·J W ParkA P Venook
Aug 1, 1964·The British Journal of Dermatology·R D SWEET

❮ Previous
Next ❯

Citations

Jul 28, 2007·Orphanet Journal of Rare Diseases·Philip R Cohen
Oct 2, 2014·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Brian A Baldo
Jul 24, 2012·Journal of Crohn's & Colitis·François AubinDaniel Wendling
May 7, 2010·European Journal of Pediatrics·Mi Jin Kim, Yon Ho Choe
Apr 11, 2006·Skinmed·Lucile E WhiteMaria M Medenica
Aug 29, 2007·Pharmacotherapy·Brychan M ClarkLaurie C D'Avignon
Aug 16, 2014·Case Reports in Radiology·O McDonnellZ Khaleel
May 18, 2011·Case Reports in Medicine·D Y Talukder, S N Delpachitra
Apr 12, 2007·The Annals of Pharmacotherapy·Dennis F Thompson, Kristin E Montarella
Apr 2, 2019·Frontiers in Immunology·Michael S Heath, Alex G Ortega-Loayza
Apr 18, 2012·Pediatrics·Paul E A GrayOrli Wargon

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Related Papers

Journal of the American Academy of Dermatology
Bradley K DraperGeorge P Stricklin
The British Journal of Dermatology
H MaillardJ L Verret
Journal of the American Academy of Dermatology
J L JorizzoB Leshin
© 2022 Meta ULC. All rights reserved